Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Oates

Showing results (201-210 of 238) with videos related to

Pageof 24
Sort By:
Arthritis Research & Therapy|January 4, 2022
Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritisM Meehan, A Shah, J Lobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2010
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II studyS Rao, N Starling, D Cunningham, et al.
British Journal of Cancer|January 1, 1997
A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomasA Rigg, D Cunningham, M Gore, et al.
British Journal of Cancer|June 12, 2003
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancerA Saini, A R Norman, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximabF Sclafani, A Roy, D Cunningham, et al.
British Journal of Cancer|June 2, 2005
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECFK Sumpter, C Harper-Wynne, D Cunningham, et al.
Journal of Biomechanical Engineering|August 23, 2025
Integrating imaging and invasive pressure data into a multi-scale whole-heart modelMarina Strocchi, Christoph M Augustin, Matthias A F Gsell, et al.
Journal of Medicinal Chemistry|September 20, 2002
A sorbitol dehydrogenase inhibitor of exceptional in vivo potency with a long duration of action: 1-(R)-[4-[4-(4,6-dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl]ethanolBanavara L Mylari, Peter J Oates, William J Zembrowski, et al.
Chemical Communications (Cambridge, England)|June 5, 2004
Plasmachemical surface functionalised beads: versatile tailored supports for polymer assisted organic synthesisJas Pal Badyal, Audrey M Cameron, Neil R Cameron, et al.
Experimental Neurology|March 10, 2005
A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic autonomic neuropathy in rats with streptozotocin-induced diabetesRobert E Schmidt, Denise A Dorsey, Lucie N Beaudet, et al.
Pageof 24

Showing results (201-210 of 238) with videos related to

Sort By:
Pageof 24
Arthritis Research & Therapy|January 4, 2022
Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritisM Meehan, A Shah, J Lobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2010
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II studyS Rao, N Starling, D Cunningham, et al.
British Journal of Cancer|January 1, 1997
A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomasA Rigg, D Cunningham, M Gore, et al.
British Journal of Cancer|June 12, 2003
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancerA Saini, A R Norman, D Cunningham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximabF Sclafani, A Roy, D Cunningham, et al.
British Journal of Cancer|June 2, 2005
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECFK Sumpter, C Harper-Wynne, D Cunningham, et al.
Journal of Biomechanical Engineering|August 23, 2025
Integrating imaging and invasive pressure data into a multi-scale whole-heart modelMarina Strocchi, Christoph M Augustin, Matthias A F Gsell, et al.
Journal of Medicinal Chemistry|September 20, 2002
A sorbitol dehydrogenase inhibitor of exceptional in vivo potency with a long duration of action: 1-(R)-[4-[4-(4,6-dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl]ethanolBanavara L Mylari, Peter J Oates, William J Zembrowski, et al.
Chemical Communications (Cambridge, England)|June 5, 2004
Plasmachemical surface functionalised beads: versatile tailored supports for polymer assisted organic synthesisJas Pal Badyal, Audrey M Cameron, Neil R Cameron, et al.
Experimental Neurology|March 10, 2005
A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic autonomic neuropathy in rats with streptozotocin-induced diabetesRobert E Schmidt, Denise A Dorsey, Lucie N Beaudet, et al.
Pageof 24